|
Treatment of Mid-Life-Related Mood Disorders Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Treatment of Mid-Life-Related Mood Disorders conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Treatment of Mid-Life-Related Mood Disorders Clinical research trials and Treatment of Mid-Life-Related Mood Disorders healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Treatment of Mid-Life-Related Mood Disorders. Treatment of Mid-Life-Related Mood Disorders Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Treatment of Mid-Life-Related Mood Disorders clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Treatment of Mid-Life-Related Mood Disorders condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Treatment of Mid-Life-Related Mood Disorders  Treatment of Mid-Life-Related Mood Disorders
Treatment of Mid-Life-Related Mood Disorders
For Condition: Depressive Disorder,Mood Disorder
Status: Completed
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: Dehydroepiandrosterone (DHEA) is a hormone produced by the adrenal gland. As humans grow older the levels of DHEA naturally decrease. Low levels of DHEA have been associated with a variety of harmful effects, including increased heart disease, decreased immune system function, decreased bone density (osteoporosis), high cholesterol, and increased fat to muscle ratio. Blood levels of DHEA and its sulfate form, DHEA-S, begin dropping when humans are in their 20's. By the time humans are in their 40's and 50's, levels of DHEA and DHEA-S levels are at 50% of their peak. Previous studies have shown that levels of these hormones are associated with feelings of "well-being" and enjoyment of "leisure" activities. In this study researchers are interested in the effects on mood and behavior of DHEA in men and women with mid-life related mood disorders. Specifically, researchers would like to find out if increasing levels of DHEA will lessen the symptoms associated with these disorders.
Details: Dehydroepiandrosterone (DHEA) is a hormone produced by the adrenal gland in concentrations that decrease with age. In humans low DHEA levels have been associated with a variety of adverse biological consequences, including increased cardiovascular disease, decreased immune function, decreased bone density, negative lipid profile and an increased fat to muscle ratio. In this study, we investigate the effects on mood and behavior of DHEA in men and women with midlife-related mood disorders in a double-blind, placebo-controlled, crossover trial. We specifically ask whether increasing DHEA levels will mitigate any or all of the neurasthenia-like symptoms characteristic of these disorders.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Subjects for this study will meet the following criteria: A current episode of minor (meeting 3-4 criterion symptoms) or major depression of moderate severity or less on the SCID severity scale for depression and not meeting DSM-IV criteria symptom #9 (suicide) as determined by the administration of the minor depression module of the SADS-L and the Structured Clinical Interview for DSM-IV. Additionally, to ensure that subjects meet a minimum threshold for severity of depression, subjects will have scores greater than or equal to 10 on either the Beck Depression Inventory (BDI) or the Center for Epidemiologic Studies - Depression (CES-D) Scale during at least three of the four clinic visits during the two month screening phase. Subjects will be excluded if they meet any of the following criteria: major depression of greater than moderate severity, DSM-IV criteria #9 (suicide), or anyone requiring immediate treatment after clinical assessment, functional impairment ratings of five or six for more than seven consecutive days on daily ratings; Age 40-65; No prior hormonal therapy for the treatment of menopause/andropause-related mood or physical symptoms within the last six months; In good medical health. EXCLUSION CRITERIA: The following conditions will constitute contradictions to treatment with DHEA and will preclude a subject's participation in this protocol: Positive (threshold) response to SCID major depression section item #9, suicidal ideation; Anyone requiring immediate treatment after clinical assessment; Severity ratings greater than moderate on the SCID; Functional impairment ratings of five or six for more than seven consecutive days on daily ratings Current treatment with antidepressant medications Prostate nodules or cancer Moderate symptoms of benign prostatic hypertrophy such as hesitancy, urgency, frequent voiding and feeling of incomplete voiding History of ischemic cardiac disease Renal disease Hepatic dysfunction Women with a history of carcinoma of the breast, or any women with a family history of the following: premenopausal breast cancer or bilateral breast cancer in a first degree relative; multiple family members (greater than three relatives) with postmenopausal breast cancer Women with a history of uterine cancer Patients with a known hypersensitivity to DHEA or other androgens Pregnant women
Total Enrollment: 60
Location and Contact Information:
National Institute of Mental Health (NIMH)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 950151; 95-M-0151
Study Start Date: June 30, 1995
Record last reviewed: April 14, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001487
Other Mood Disorder Studies:
1. Clinical Trial of Fluoxetine in Anxiety and Depression in Children, and Associated Brain Changes
2. Study of Menstrually-Regulated Mood and Behavioral Disorder
3. Neuropsychological Evaluation of Psychiatric and Neurological Patients
4. Evaluation of the Genetics of Bipolar Disorder
5. Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
Related Studies:
Other Mood Disorder Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Treatment of Mid-Life-Related Mood Disorders
|
|
|
|
|
|
|
|
